Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious illnesses such as coronaviruses and multidrug-resistant pathogens. Terra CoV-2 which is OGEN’s main product is a vaccination candidate for COVID-19 and SARS-CoV-2 viral subtypes.
Important Development for OGEN stock
Oragenics reported today that the company has reached a deal with the National Research Council of Canada (NRC) to explore the quick growth of next-generation vaccines against the SARS-CoV-2 virus and its variations. Oragenics now has a platform that can create cell lines for the high-yield synthesis of spike protein antigens for existing and upcoming variations of concern, thanks to NRC technology in conjunction with NIH components present in the Company’s Terra CoV-2 vaccine.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
This technology should enable cell lines to be produced in six to eight weeks once the spike gene sequence is available, as opposed to six to nine months for typical cell line manufacturing. The NRC technologies will speed up the assessment of SARS-CoV-2 antigen candidates in clinical and preclinical investigations, owing to funding from the NRC’s Pandemic Response Challenge Program.
Frederick W. Telling, Oragenics’ Executive Chairman commented,
The signing of this license deal, as well as a separate material transfer contract with the NRC, is likely to have a significant and beneficial influence on the company’s strategic orientation, and they hope to move forward with the manufacture of next-generation SARS-CoV-2 vaccines.
In terms of their possible future competitive posture against presently available SARS-CoV-2 vaccines, they think that the licensed technology will speed up development, while the capacity to swiftly create new vaccine antigens will allow them to quickly address new variations as they occur. Furthermore, their partnership with Biodextris for an intranasal adjuvant is intended to complement their intramuscular delivery choices. It also provides Oragenics with numerous antigen-adjuvant alternatives in the event that SARS-CoV-2 evolves into a seasonal flu-like illness, as many experts predict.